Prediction of Parkinson's disease pathogenic variants using hybrid Machine learning systems and radiomic features.


Journal

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
ISSN: 1724-191X
Titre abrégé: Phys Med
Pays: Italy
ID NLM: 9302888

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 11 08 2022
revised: 08 05 2023
accepted: 29 07 2023
medline: 18 9 2023
pubmed: 14 8 2023
entrez: 14 8 2023
Statut: ppublish

Résumé

In Parkinson's disease (PD), 5-10% of cases are of genetic origin with mutations identified in several genes such as leucine-rich repeat kinase 2 (LRRK2) and glucocerebrosidase (GBA). We aim to predict these two gene mutations using hybrid machine learning systems (HMLS), via imaging and non-imaging data, with the long-term goal to predict conversion to active disease. We studied 264 and 129 patients with known LRRK2 and GBA mutations status from PPMI database. Each dataset includes 513 features such as clinical features (CFs), conventional imaging features (CIFs) and radiomic features (RFs) extracted from DAT-SPECT images. Features, normalized by Z-score, were univariately analyzed for statistical significance by the t-test and chi-square test, adjusted by Benjamini-Hochberg correction. Multiple HMLSs, including 11 features extraction (FEA) or 10 features selection algorithms (FSA) linked with 21 classifiers were utilized. We also employed Ensemble Voting (EV) to classify the genes. For prediction of LRRK2 mutation status, a number of HMLSs resulted in accuracies of 0.98 ± 0.02 and 1.00 in 5-fold cross-validation (80% out of total data points) and external testing (remaining 20%), respectively. For predicting GBA mutation status, multiple HMLSs resulted in high accuracies of 0.90 ± 0.08 and 0.96 in 5-fold cross-validation and external testing, respectively. We additionally showed that SPECT-based RFs added value to the specific prediction of of GBA mutation status. We demonstrated that combining medical information with SPECT-based imaging features, and optimal utilization of HMLS can produce excellent prediction of the mutations status in PD patients.

Identifiants

pubmed: 37579523
pii: S1120-1797(23)00124-2
doi: 10.1016/j.ejmp.2023.102647
pii:
doi:

Substances chimiques

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 EC 2.7.11.1
Glucosylceramidase EC 3.2.1.45

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102647

Informations de copyright

Copyright © 2023 Associazione Italiana di Fisica Medica e Sanitaria. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ghasem Hajianfar (G)

Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran; Technological Virtual Collaboration (TECVICO Corp.), Vancouver BC, Canada.

Samira Kalayinia (S)

Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

Mahdi Hosseinzadeh (M)

Technological Virtual Collaboration (TECVICO Corp.), Vancouver BC, Canada; Department of Electrical and Computer Engineering, Tarbiat Modares University, Tehran, Iran.

Sara Samanian (S)

Firoozgar Hospital Medical Genetics Laboratory, Iran University of Medical Sciences, Tehran, Iran.

Majid Maleki (M)

Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

Vesna Sossi (V)

Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada.

Arman Rahmim (A)

Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.

Mohammad R Salmanpour (MR)

Technological Virtual Collaboration (TECVICO Corp.), Vancouver BC, Canada; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada. Electronic address: msalman@bccrc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH